Loading...
XTAE
BOLT
Market cap5mUSD
Dec 04, Last price  
324.90ILS
1D
1.18%
1Q
-39.51%
Jan 2017
-74.51%
IPO
-99.32%
Name

Biolight Life Sciences Ltd

Chart & Performance

D1W1MN
XTAE:BOLT chart
P/E
—
P/S
77.89
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.50%
Rev. gr., 5y
-5.91%
Revenues
219k
+85.59%
52,00082,000941,0001,391,0002,111,0001,209,0003,687,000297,00031,0003,00063,000118,000219,000
Net income
-7m
L-72.55%
-13,356,000-18,837,000-23,102,000-19,259,000-21,824,000-17,260,00065,385,000-12,591,000-13,382,000382,000-7,847,000-26,020,000-7,142,000
CFO
-11m
L+14.80%
-19,460,000-26,225,000-26,987,000-24,037,000-26,942,000-25,318,000-22,390,000-15,357,000-11,395,000-10,026,000-9,540,000-9,577,000-10,994,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of product candidates include DiagnosTear's TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops; ViSci, an Eye D technology that treats glaucoma by the insertion of a sub conjunctival implant; OphRx that develops drugs for treating eye diseases; and Peripherex, which develops solutions for at-home and in-office diagnosis and monitoring of peripheral vision impairment used by eye care and other providers to diagnose and monitor glaucoma and other diseases. Its pipeline also include AEYE that develops artificial intelligence solutions for a variety of retinal diseases; Tarsier, which develops TRS 01 based on its technological platform for the treatment of Uveitis in patients suffering from high IPO; Belkin Vision that develops clinic fast and automatic laser device to enable glaucoma patients to receive short & effective treatments as treatment to lower IOP; and Sanoculis, which develops an innovative surgical procedure for the treatment of the Glaucoma. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was incorporated in 2005 and is based in Tel Aviv, Israel.
URL
https://www.bio-light.co.il
IPO date
Dec 27, 2005
Employees
5
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT